Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.

Journal of clinical pharmacology - 1 Oct 2020

Elmeliegy Mohamed, Yu Yanke, Litton Jennifer K, Czibere Akos, Wilson Gary G, Tudor Iulia Cristina, Zheng Jenny, Wang Diane D

Abstract excerpt

Poly(ADP-ribose) polymerase inhibitors, such as talazoparib, may affect hematopoiesis. This analysis characterized the relationship between talazoparib exposure and the most common grade ≥ 3 hematopoietic adverse events (AEs) leading to dose modification in the phase 2 (ABRAZO) and phase 3 (EMBRACA) trials. The relationship between time-varying average talazoparib concentration (Cavg,t ), along with other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Drug Dosage Calculations

Share to Neutropenia

Share to Phthalazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Thrombocytopenia

Source

Identifiers

PMID: 32468645
DOI: 10.1002/jcph.1626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.PMID 32468645Read ↗

Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancerSemantic proximity Read ↗

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis.Semantic proximity Read ↗

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic CancersSemantic proximity Read ↗

Safety, Pharmacokinetics, and Preliminary Efficacy of Talazoparib in Japanese Patients With Advanced Solid Tumors: Phase 1 StudySemantic proximity Read ↗

Evidence to date: talazoparib in the treatment of breast cancerSemantic proximity Read ↗

Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSemantic proximity Read ↗

Cost-Effectiveness Analysis of talazoparib Maintenance Treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the USSemantic proximity Read ↗

Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Talazoparib to treat BRCA-positive breast cancerSemantic proximity Read ↗

Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program.Semantic proximity Read ↗

Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.Semantic proximity Read ↗

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.